A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2017
At a glance
- Drugs PL 0264 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Delta-Fly Pharma
- 18 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 02 Jun 2015 According to ProLynx media release, Investigational New Drug (IND) application for PL 0264 (PEG-SN-38) filed with US FDA is active and this trial is expected to initiate in 2015.
- 07 May 2015 New trial record